Brief: Revive Therapeutics Provides Update On Phase 3 Clinical Trial For Bucillamine In Covid-19
25/04/2022 21:54
April 25 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON PHASE 3 CLINICAL
TRIAL
FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD - HAS MADE EFFORTS IN DETERMINING
APPROPRIATE PRIMARY AND SECONDARY CLINICAL ENDPOINTS FOR FDA
CONSIDERATION
Source text for Eikon: ID:nGNX704qmz
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure